Purpose: Firstly, the aim of this study was to determine the maximally tolerated dose of intravitreally injected povidone-iodine (PVP-I). A second aim was to test the efficacy of PVP-I on rabbit eyes infected intravitreally with Staphylococcus epidermidis.
Methods: Phase I of the study used 16 New Zealand albino rabbits, divided into 4 groups (n=4 each). Animals were anesthetized and intravitreally injected with 0.1 mL of 50, 100, 200, or 400 micrograms (microg) of PVP-I in 1 eye, and with saline in the other. The animals were examined at days 1, 7, and 14, using indirect ophthalmoscopy and slit-lamp biomicroscopy; electroretinography (ERG) was performed before treatment and prior to euthanization. Histological preparations were examined to determine retinal damage. Phase II of the study divided 20 New Zealand albino rabbits into 4 groups (n=5 each). Animals were anesthetized and injected with 0.1 mL of S. epidermidis containing 3030 colony forming units (CFU) in 1 eye and saline in the other. Seven (7) h later, animals were treated with 0.1 mL of 20, 50, and 100 microg of PVP-I, or no treatment. Bacterial concentrations from extracted vitreous were determined 2 days following infection. Results were analyzed for statistical significance, using the Student t test and analysis of variance, and histologic preparations assessed the presence of endophthalmitis.
Results: Phase I of the study observed no retinal damage at any of the concentrations studied, as noted by indirect ophthalmoscopy, slit-lamp biomicroscopy, ERG, and histologic exam. Phase II of the study showed no statistical difference in bacterial counts between treatment and control groups. All infected eyes went on to develop endophthalmitis, as observed by indirect ophthalmoscopy and histologic preparations.
Conclusions: These results suggest that 400_g of PVP-I can be tolerated intravitreally in rabbit eyes with no noticeable damage over a 14-day period. Results further showed that 100 microg of intravitreally injected PVP-I has no statistically significant effect on rabbit eyes injected intravitreally with 3030 CFU of S. epidermidis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/jop.2006.0076 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-World Results in Treating Diabetic Macular Edema With Faricimab at a London-Based Tertiary Eye Hospital.
Cureus
December 2024
Ophthalmology, Western Eye Hospital, Imperial College Healthcare NHS Trust, London, GBR.
Diabetic macular edema (DMO) poses a significant risk to vision, primarily caused by the leakage of retinal vessels. Traditional treatments involve anti-vascular endothelial growth factor (VEGF) agents and corticosteroids, though responses vary, necessitating frequent treatments. This retrospective study at a London-based tertiary eye hospital evaluates the efficacy of faricimab, a bispecific antibody inhibiting angiopoietin 2 (Ang-2) and VEGF-A, in treating DMO.
View Article and Find Full Text PDFMalignant Transformation of a Choroidal Nevus.
Cureus
December 2024
Department of Ophthalmology, Xi'an No. 3 Hospital, the Affiliated Hospital of Northwest University, Xi'an, CHN.
Choroidal nevus is the most common intraocular tumor, and most cases are benign and have no symptoms. However, choroidal nevus carries a low risk for transformation into melanoma, which is a highly aggressive and deadly cancer. In this case report, we present a male patient with blurred vision in his left eye for six months.
View Article and Find Full Text PDFReal-World-Data of Treatment-Naïve and Previously Treated Patients Receiving Up to 3 Injections of Faricimab in Neovascular Age-Related Macular Degeneration.
Clin Ophthalmol
December 2024
University Eye Hospital, Centre for Ophthalmology, University of Tuebingen, Tuebingen, Germany.
Purpose: To evaluate visual and anatomical outcome of consecutive patients who received intravitreal injections (IVI) of faricimab for the treatment of neovascular age-related macular degeneration (nAMD).
Patients And Methods: A retrospective study of patients treated for nAMD with one to three IVIs of faricimab from October 2022 to January 2024. Demographic data, treatment history, best corrected visual acuity (BCVA), anatomic parameters, and adverse events (AEs) were collected.
Primary scleral buckling vs. vitrectomy for stage 4A retinopathy of prematurity: a systematic review and meta-analysis of surgical outcomes.
Eye (Lond)
January 2025
Dean McGee Eye Institute, Department of Ophthalmology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Topic: To compare anatomic outcomes of primary scleral buckle (SB) vs. lens sparing pars plana vitrectomy (LSV) in treating retinopathy of prematurity (ROP) associated Stage 4A retinal detachment (RD).
Clinical Relevance: ROP is the leading cause of blindness in childhood in industrialized countries worldwide.
Wearable electrodriven switch actively delivers macromolecular drugs to fundus in non-invasive and controllable manners.
Nat Commun
January 2025
Suzhou Key Laboratory of Nanotechnology and Biomedicine, Institute of Functional Nano & Soft Materials & Collaborative Innovation Center of Suzhou Nano Science and Technology (NANO-CIC), Soochow University, Suzhou, China.
Current treatments for fundus disorders, such as intravitreal injections, pose risks, including infection and retinal detachment, and are limited in their ability to deliver macromolecular drugs across the blood‒retinal barrier. Although non-invasive methods are safer, their delivery efficiency remains suboptimal (<5%). We have developed a wearable electrodriven switch (WES) that improves the non-invasive delivery of macromolecules to the fundus.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!